{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:11:03Z","timestamp":1785431463290,"version":"3.56.0"},"reference-count":144,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["25-73-20033"],"award-info":[{"award-number":["25-73-20033"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"award":["25-73-20033"],"award-info":[{"award-number":["25-73-20033"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>The review covers research on dual-target antitumor agents over the past five years. One of the targets is histone deacetylases (HDACs), while the second potential target is a protein group located both on the membrane surface (phosphatidylinositol 3-kinase (PI3K), anaplastic lymphoma kinase (ALK), receptor tyrosine kinase (AXL), tyrosine protein kinase (HER2), FMS-like tyrosine kinase (FLT3), and vascular endothelial growth factor receptor (VEGFR2)) and in the nucleus (serine\/threonine protein kinase Wee1, DNA methyltransferase (DNMT), dual-specificity phosphatase (CDC25A), an enzyme from the cyclin-dependent kinase family (CDK9), dual-specificity tyrosine-serine\/threonine kinase (DYRK2), and BET family proteins (BRD4, BD1, and BD2)). This review presents the results of studies on the inhibitory activity of various HDAC isoforms and other enzymes, as well as in vitro cytotoxicity studies on both neoplastic and healthy cells. It also includes selectivity studies, in vivo experiments (changes in tumor volume in mice) and oral bioavailability assessments. The review also describes the chemical structures of several dual-target agents and identifies the molecular fragments responsible for inhibiting different targets. Based on the studies reviewed in this paper, it can be concluded that some dual inhibitors have superior in vitro cytotoxicity and exhibit selectivity towards some tumor cells compared to monofunctional reference compounds. These findings may be useful for molecular design in the field of polypharmacology, with the aim of developing new dual-target molecules that exhibit improved antitumor activity and selectivity towards neoplastic cells.<\/jats:p>","DOI":"10.3390\/ijms27156604","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:47:41Z","timestamp":1785145661000},"page":"6604","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Research in Polypharmacology for Cancer Treatment Using Dual-Target Histone Deacetylase Inhibitors"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-4696","authenticated-orcid":false,"given":"Pavel","family":"Yudaev","sequence":"first","affiliation":[{"name":"Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilova St., 28, Bld. 1, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5370-3370","authenticated-orcid":false,"given":"Yulia","family":"Aleksandrova","sequence":"additional","affiliation":[{"name":"Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilova St., 28, Bld. 1, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-5920","authenticated-orcid":false,"given":"Margarita","family":"Neganova","sequence":"additional","affiliation":[{"name":"Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilova St., 28, Bld. 1, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.drudis.2022.04.011","article-title":"Recent Advances in Dual-Ligand Targeted Nanocarriers for Cancer Therapy","volume":"27","author":"Khan","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_2","first-page":"7","article-title":"Cancer Statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5487\/TR.2017.33.1.001","article-title":"Oxidative Stress, Nrf2, and Epigenetic Modification Contribute to Anticancer Drug Resistance","volume":"33","author":"Kang","year":"2017","journal-title":"Toxicol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"217410","DOI":"10.1016\/j.canlet.2024.217410","article-title":"STING in Cancer Immunoediting: Modeling Tumor-Immune Dynamics throughout Cancer Development","volume":"612","author":"Zhang","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tripathi, A.K., and Vishwanatha, J.K. (2022). Role of Anti-Cancer Peptides as Immunomodulatory Agents: Potential and Design Strategy. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122686"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s40495-022-00289-6","article-title":"The Effectiveness of Various Chemotherapeutic Agents in Cancer Treatment","volume":"8","author":"Lavanya","year":"2022","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13148-025-01961-6","article-title":"Regulation of Cisplatin Resistance in Lung Cancer by Epigenetic Mechanisms","volume":"17","author":"Yu","year":"2025","journal-title":"Clin. Epigenet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","article-title":"Targeting Epigenetic Regulators for Cancer Therapy: Mechanisms and Advances in Clinical Trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40478-025-02194-7","article-title":"Targeting Glioblastoma with HDAC Inhibitors: Insights into Hydroxamic Acid-Based Therapeutic Strategies","volume":"14","author":"Pai","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41419-025-08295-4","article-title":"Identification of Targetable Epigenetic Vulnerabilities for Uveal Melanoma","volume":"17","author":"Yenisehirli","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"115416","DOI":"10.1016\/j.colsurfb.2026.115416","article-title":"Esterase-Activatable Dimeric HDAC Inhibitor Nanotherapeutics for Enhanced Lymphoma Epigenetic Therapy","volume":"261","author":"Li","year":"2026","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9314","DOI":"10.1039\/D4RA00050A","article-title":"Design, Synthesis and Activity Evaluation of Arctigenin Derivatives with HDAC Inhibition Activity","volume":"14","author":"Jiang","year":"2024","journal-title":"RSC Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic Regulation in Human Cancer: The Potential Role of Epi-Drug in Cancer Therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"189150","DOI":"10.1016\/j.bbcan.2024.189150","article-title":"Histone Deacetylase Complexes: Structure, Regulation and Function","volume":"1879","author":"Asmamaw","year":"2024","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"116696","DOI":"10.1016\/j.ejmech.2024.116696","article-title":"Overview of Class I HDAC Modulators: Inhibitors and Degraders","volume":"276","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/med.21320","article-title":"Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy","volume":"35","author":"Zhang","year":"2015","journal-title":"Med. Res. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yudaev, P., Aleksandrova, Y., and Neganova, M. (2025). Recent Insights into the Creation of Histone Deacetylase Inhibitors for the Treatment of Human Diseases. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178629"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1039\/D5RA09034B","article-title":"HDAC Inhibitors as Anticancer Drugs: Chemical Diversity, Clinical Trials, Challenges and Perspectives","volume":"16","author":"Abdallah","year":"2026","journal-title":"RSC Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100165","DOI":"10.1016\/j.lddd.2025.100165","article-title":"Structural Classification of HDAC Inhibitors and Cancer Treatment Prospects: A Review","volume":"22","author":"Ji","year":"2025","journal-title":"Lett. Drug Des. Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.2174\/0109298673332285241104091609","article-title":"Structural Modifications and Prospects of Histone Deacetylase (HDAC) Inhibitors in Cancer","volume":"32","author":"Chen","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/13543776.2025.2591483","article-title":"Patent Landscape in Hydroxamic Acid-Based HDAC Inhibitors (2020\u20132024): Structure\u2013Activity Relationships and Mechanistic Insights","volume":"36","author":"Shirbhate","year":"2026","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination Therapy in Combating Cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tips.2004.12.002","article-title":"Overcoming Limitations of Natural Anticancer Drugs by Combining with Artificial Agents","volume":"26","author":"Blagosklonny","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"188866","DOI":"10.1016\/j.bbcan.2023.188866","article-title":"Therapeutic Strategies of Dual-Target Small Molecules to Overcome Drug Resistance in Cancer Therapy","volume":"1878","author":"Ye","year":"2023","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"112025","DOI":"10.1016\/j.ejmech.2019.112025","article-title":"Dual-Target Kinase Drug Design: Current Strategies and Future Directions in Cancer Therapy","volume":"188","author":"Sun","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: Challenges and Opportunities in Drug Discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tran, C., and Hamze, A. (2025). Recent Advancements in the Development of HDAC\/Tubulin Dual-Targeting Inhibitors. Pharmaceuticals, 18.","DOI":"10.3390\/ph18030341"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108847","DOI":"10.1016\/j.bioorg.2025.108847","article-title":"The LSD1\/HDAC Dual-Target Inhibitor for Cancer Therapy: Challenge and Opportunity","volume":"164","author":"Shen","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","article-title":"The Relation between PI3K\/AKT Signalling Pathway and Cancer","volume":"698","author":"Noorolyai","year":"2019","journal-title":"Gene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt Signalling Pathway and Cancer","volume":"30","author":"Vara","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt Signal Transduction for Cancer Therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1467-789X.2009.00607.x","article-title":"Obesity, the PI3K\/Akt Signal Pathway and Colon Cancer","volume":"10","author":"Huang","year":"2009","journal-title":"Obes. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","article-title":"The PI3K\/AKT Pathway as a Target for Cancer Treatment","volume":"67","author":"Mayer","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"B271","DOI":"10.1158\/1535-7163.TARG-13-B271","article-title":"Abstract B271: A First-in-Human Phase I Study of ZSTK474, an Oral Pan-PI3K Inhibitor, in Patients with Advanced Solid Malignancies","volume":"12","author":"Lockhart","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/cmdc.202000643","article-title":"Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects","volume":"16","author":"Rodrigues","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.soc.2013.06.008","article-title":"Targeting the PI3-Kinase\/Akt\/MTOR Signaling Pathway","volume":"22","author":"Hassan","year":"2013","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/MTOR and RAF\/MEK\/ERK Pathways for Cancer Therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol. Biomed."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/s41388-018-0550-3","article-title":"Dual Inhibition of PI3K Signaling and Histone Deacetylation Halts Proliferation and Induces Lethality in Mantle Cell Lymphoma","volume":"38","author":"Guo","year":"2019","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V126.23.257.257","article-title":"Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma","volume":"126","author":"Younes","year":"2015","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41420-025-02470-4","article-title":"The Dual HDAC\/PI3K Inhibitor CUDC-907 Inhibits the Growth and Proliferation of MYC-Driven Group 3 Medulloblastoma","volume":"11","author":"Gou","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"117658","DOI":"10.1016\/j.ejmech.2025.117658","article-title":"Discovery of Hydrazide-Based PI3K\/HDAC Dual Inhibitors with Enhanced pro-Apoptotic Activity in Lymphoma Cells","volume":"292","author":"Hou","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1021\/acs.jmedchem.1c01472","article-title":"Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo","volume":"65","author":"Jiang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/aps.2010.150","article-title":"ZSTK474, a Novel Phosphatidylinositol 3-Kinase Inhibitor Identified Using the JFCR39 Drug Discovery System","volume":"31","author":"Kong","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"118170","DOI":"10.1016\/j.ejmech.2025.118170","article-title":"Design, Synthesis and Bioactive Evaluation of Novel Quinoline-Linked Sulfonamide-Pyridine Derivatives as PI3K\/HDAC Dual-Target Inhibitors","volume":"301","author":"Sun","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2024.07.009","article-title":"Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes from the GuardantINFORM Database","volume":"19","author":"Parikh","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular Targeting Therapies for Neuroblastoma: Progress and Challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cac2.12038","article-title":"Association of an Anaplastic Lymphoma Kinase Pathway Signature with Cell De-Differentiation, Neoadjuvant Chemotherapy Response, and Recurrence Risk in Breast Cancer","volume":"40","author":"Liu","year":"2020","journal-title":"Cancer Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/ERC-20-0436","article-title":"Targeting EML4-ALK Gene Fusion Variant 3 in Thyroid Cancer","volume":"28","author":"Aydemirli","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2022.02.001","article-title":"Dramatic Response to Brigatinib in a Lung Adenocarcinoma Patient Harboring EML4-ALK Fusion and a G1202R de Novo Gene Mutation","volume":"165","author":"Pan","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2020.04.002","article-title":"HDAC Inhibition Synergizes with ALK Inhibitors to Overcome Resistance in a Novel ALK Mutated Lung Adenocarcinoma Model","volume":"144","author":"Stockhammer","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"113672","DOI":"10.1016\/j.ejmech.2021.113672","article-title":"Discovery of 2,4-Pyrimidinediamine Derivatives as Potent Dual Inhibitors of ALK and HDAC","volume":"224","author":"Pan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2318645","DOI":"10.1080\/14756366.2024.2318645","article-title":"Discovery of Novel Anaplastic Lymphoma Kinase (ALK) and Histone Deacetylase (HDAC) Dual Inhibitors Exhibiting Antiproliferative Activity against Non-Small Cell Lung Cancer","volume":"39","author":"Wang","year":"2024","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm3005866","article-title":"The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer","volume":"55","author":"Lewis","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"130495","DOI":"10.1016\/j.bmcl.2025.130495","article-title":"Design, Synthesis and Biological Evaluation of ALK\/HDAC Dual-Targeting Agents","volume":"133","author":"Kong","year":"2026","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1158\/0008-5472.CAN-17-0392","article-title":"AXL-Driven EMT State as a Targetable Conduit in Cancer","volume":"77","author":"Antony","year":"2017","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wium, M., Ajayi-smith, A.F., Paccez, J.D., and Zerbini, L.F. (2021). The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications. Cancers, 13.","DOI":"10.3390\/cancers13071521"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Sang, Y.B., Kim, J.H., Kim, C.G., Hong, M.H., Kim, H.R., Cho, B.C., and Lim, S.M. (2022). The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.811247"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1038\/onc.2013.388","article-title":"The Receptor Tyrosine Kinase Axl Regulates Cell-Cell Adhesion and Stemness in Cutaneous Squamous Cell Carcinoma","volume":"33","author":"Szentpetery","year":"2014","journal-title":"Oncogene"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.drudis.2020.09.022","article-title":"Therapeutic Aspects of the Axl\/Gas6 Molecular System","volume":"25","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL Receptor Tyrosine Kinase as a Promising Anti-Cancer Approach: Functions, Molecular Mechanisms and Clinical Applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2022.01.007","article-title":"Chidamide and Mitomycin C Exert Synergistic Cytotoxic Effects against Bladder Cancer Cells in Vitro and Suppress Tumor Growth in a Rat Bladder Cancer Model","volume":"530","author":"Wang","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1535-7163.MCT-12-1045","article-title":"Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion","volume":"12","author":"Wang","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3727\/096504016X14648701447814","article-title":"Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1\/2 in Non-Small Cell Lung Cancer Cells","volume":"24","author":"Tian","year":"2016","journal-title":"Oncol. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3892\/ijo.2015.3216","article-title":"Curcumin-Induced Downregulation of Axl Receptor Tyrosine Kinase Inhibits Cell Proliferation and Circumvents Chemoresistance in Non-Small Lung Cancer Cells","volume":"47","author":"Kim","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2295241","DOI":"10.1080\/14756366.2023.2295241","article-title":"Discovery of Novel and Potent Dual-Targeting AXL\/HDAC2 Inhibitors for Colorectal Cancer Treatment via Structure-Based Pharmacophore Modelling, Virtual Screening, and Molecular Docking, Molecular Dynamics Simulation Studies, and Biological Evaluation","volume":"39","author":"Qiao","year":"2024","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the Extracellular Region of HER2 Alone and in Complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","article-title":"HER2-Targeted Therapies in Cancer: A Systematic Review","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Xia, X., Gong, C., Zhang, Y., and Xiong, H. (2023). The History and Development of HER2 Inhibitors. Pharmaceuticals, 16.","DOI":"10.3390\/ph16101450"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1517\/14712598.7.2.257","article-title":"Lapatinib: A Dual Inhibitor of EGFR and HER2 Tyrosine Kinase Activity","volume":"7","author":"Montemurro","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.2165\/11203240-000000000-00000","article-title":"Lapatinib: A Review of Its Use in the Treatment of HER2-Overexpressing, Trastuzumab-Refractory, Advanced or Metastatic Breast Cancer","volume":"69","author":"Frampton","year":"2009","journal-title":"Drugs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"13424","DOI":"10.1038\/s41598-025-97786-7","article-title":"In Silico and in Vitro Evaluation of the Anticancer Effect of a 1,5-Benzodiazepin-2-One Derivative (3b) Revealing Potent Dual Inhibition of HER2 and HDAC1","volume":"15","author":"Bakheit","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Lahmidi, S., Bakheit, A.H., Essassi, E.M., Mague, J.T., and Alanazi, M.M. (2023). X-Ray Crystal Structure, Hirshfeld Surface Analysis, DFT, and Anticancer Effect of 3-Hydroxy-4-Phenyl-1,5- Benzodiazepin-2-One Derivatives Sanae. Crystals, 13.","DOI":"10.3390\/cryst13121693"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Wang, X., Bove, A.M., Simone, G., and Ma, B. (2020). Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.599281"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","article-title":"Vascular Endothelial Growth Factor Receptor-2: Structure, Function, Intracellular Signalling and Therapeutic Inhibition","volume":"19","author":"Holmes","year":"2007","journal-title":"Cell. Signal."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jprot.2017.08.015","article-title":"Quantitative Phosphoproteomic Analysis of Acquired Cancer Drug Resistance to Pazopanib and Dasatinib","volume":"170","author":"Vyse","year":"2018","journal-title":"J. Proteom."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7150\/thno.16767","article-title":"Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors","volume":"7","author":"Torok","year":"2017","journal-title":"Theranostics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1021\/acs.jmedchem.8b00384","article-title":"Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously","volume":"61","author":"Zang","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1021\/acs.jmedchem.8b00189","article-title":"Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy","volume":"62","author":"Luan","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2015.12.033","article-title":"Design, Synthesis and Biological Evaluation of N-Phenylquinazolin-4-Amine Hybrids as Dual Inhibitors of VEGFR-2 and HDAC","volume":"109","author":"Peng","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"28462","DOI":"10.1039\/D3RA05542F","article-title":"Design, Synthesis and Biological Evaluation of VEGFR-2\/HDAC Dual Inhibitors as Multitargeted Antitumor Agents Based on Fruquintinib and Vorinostat","volume":"13","author":"Gao","year":"2023","journal-title":"RSC Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/10428194.2013.800198","article-title":"FLT3 Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia: Clinical Implications and Limitations","volume":"55","author":"Kayser","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/ejh.12841","article-title":"Bin The Role of FLT3 Inhibitors in the Treatment of FLT3-Mutated Acute Myeloid Leukemia","volume":"98","author":"Fathi","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1634\/stemcells.2005-0519","article-title":"FMS-Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia","volume":"24","author":"Parcells","year":"2006","journal-title":"Stem Cells"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/blood.V87.3.1089.bloodjournal8731089","article-title":"Expression of the Hematopoietic Growth Factor Receptor FLT3 (STK-1\/Flk2) in Human Leukemias","volume":"87","author":"Carow","year":"1996","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 Inhibitors in Acute Myeloid Leukemia: Ten Frequently Asked Questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00204-021-03174-1","article-title":"Inhibitors of Class I HDACs and of FLT3 Combine Synergistically against Leukemia Cells with Mutant FLT3","volume":"96","author":"Wachholz","year":"2022","journal-title":"Arch. Toxicol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-139696","article-title":"Antimetabolic Cooperativity with L-Asparaginase and Tyrosine Kinase Inhibitor Quizartinib to Eradicate Persistant FLT3-ITD Leukemic Cells","volume":"136","author":"Fovez","year":"2020","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"118574","DOI":"10.1016\/j.ejmech.2026.118574","article-title":"Discovery of Novel Aminopyrimidine-Hydroxamate Derivatives as Dual FLT3\/HDAC Inhibitors: Design, Synthesis, and Anti-Hematologic Malignancy Evaluation","volume":"305","author":"Ran","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0092-8674(87)90458-2","article-title":"Negative Regulation of Mitosis by Wee1+, a Gene Encoding a Protein Kinase Homolog","volume":"49","author":"Russell","year":"1987","journal-title":"Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting Replication Stress in Cancer Therapy","volume":"22","author":"Chowdhury","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10637-023-01371-6","article-title":"A Phase Ib Study of Adavosertib, a Selective Wee1 Inhibitor, in Patients with Locally Advanced or Metastatic Solid Tumors","volume":"41","author":"Falchook","year":"2023","journal-title":"Investig. New Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-014-0053-9","article-title":"CHK1 Plays a Critical Role in the Anti-Leukemic Activity of the Wee1 Inhibitor MK-1775 in Acute Myeloid Leukemia Cells","volume":"7","author":"Qi","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41467-018-03096-0","article-title":"HDAC1 and HDAC2 Integrate Checkpoint Kinase Phosphorylation and Cell Fate through the Phosphatase-2A Subunit PR130","volume":"9","author":"Emmerich","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"22845","DOI":"10.1021\/acs.jmedchem.5c01789","article-title":"Discovery of Novel and Highly Potent Wee1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrg3270","article-title":"DNA Methylation Profiling in the Clinic: Applications and Challenges","volume":"13","author":"Heyn","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhang, J., Yang, C., Wu, C., Cui, W., and Wang, L. (2020). DNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy. Cancers, 12.","DOI":"10.3390\/cancers12082123"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41416-018-0025-x","article-title":"DNMTi\/HDACi Combined Epigenetic Targeted Treatment Induces Reprogramming of Myeloma Cells in the Direction of Normal Plasma Cells","volume":"118","author":"Bruyer","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Al-Kharashi, L.A., Tulbah, A., Arafah, M., Eldali, A.M., Al-Tweigeri, T., and Aboussekhra, A. (2022). High DNMT1 Expression in Stromal Fibroblasts Promotes Angiogenesis and Unfavorable Outcome in Locally Advanced Breast Cancer Patients. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.877219"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1541-7786.MCR-07-0330","article-title":"Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells","volume":"6","author":"Zhou","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41420-024-01895-7","article-title":"Dual Inhibitors of DNMT and HDAC Induce Viral Mimicry to Induce Antitumour Immunity in Breast Cancer","volume":"10","author":"Huang","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejmech.2017.04.017","article-title":"Design, Synthesis and Anticancer Potential of NSC-319745 Hydroxamic Acid Derivatives as DNMT and HDAC Inhibitors","volume":"134","author":"Yuan","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"19022","DOI":"10.1021\/acs.jmedchem.5c01092","article-title":"Design, Synthesis, and Biological Evaluation of Quinoline-Based Hydroxamic Acid Derivatives as Dual DNMT and HDAC Inhibitors with Potent Anti-Breast Cancer Activity","volume":"68","author":"Lin","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"107271","DOI":"10.1016\/j.phrs.2024.107271","article-title":"Dual Inhibitors of DNMT and HDAC Remodels the Immune Microenvironment of Colorectal Cancer and Enhances the Efficacy of Anti-PD-L1 Therapy","volume":"206","author":"Yang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Dakilah, I., Harb, A., Abu-Gharbieh, E., El-Huneidi, W., Taneera, J., Hamoudi, R., Semreen, M.H., and Bustanji, Y. (2024). Potential of CDC25 Phosphatases in Cancer Research and Treatment: Key to Precision Medicine. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1324001"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2014.01.022","article-title":"Novel Anti-Inflammatory Function of NSC95397 by the Suppression of Multiple Kinases","volume":"88","author":"Yang","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41598-019-38579-7","article-title":"Pharmacophore-Guided Discovery of CDC25 Inhibitors Causing Cell Cycle Arrest and Tumor Regression","volume":"9","author":"Kabakci","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.2174\/1568026619666181224095449","article-title":"Epigenetic Targets and Their Inhibitors in Cancer Therapy","volume":"18","author":"Zhao","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s10495-024-02023-7","article-title":"Novel Dual Inhibitor Targeting CDC25 and HDAC for Treating Triple-Negative Breast Cancer","volume":"29","author":"Sethy","year":"2024","journal-title":"Apoptosis"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"118816","DOI":"10.1016\/j.biopha.2025.118816","article-title":"A Novel Dual CDC25-HDAC Inhibitor Suppresses Glioblastoma Progression via Chromosomal Passenger Complex Disruption","volume":"193","author":"Upadhyay","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.tips.2008.03.003","article-title":"Cyclin-Dependent Kinase 9: A Key Transcriptional Regulator and Potential Drug Target in Oncology, Virology and Cardiology","volume":"29","author":"Wang","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.apsb.2021.10.024","article-title":"Inhibition of the CDK9\u2013Cyclin T1 Protein\u2013Protein Interaction as a New Approach against Triple-Negative Breast Cancer","volume":"12","author":"Cheng","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1128\/MCB.22.13.4622-4637.2002","article-title":"Phosphorylation of the RNA Polymerase II Carboxyl-Terminal Domain by CDK9 Is Directly Responsible for Human Immunodeficiency Virus Type 1 Tat-Activated Transcriptional Elongation","volume":"22","author":"Kim","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"37305","DOI":"10.18632\/oncotarget.26468","article-title":"Antineoplastic Effects of Selective CDK9 Inhibition with Atuveciclib on Cancer Stem-like Cells in Triple-Negative Breast Cancer","volume":"9","author":"Brisard","year":"2018","journal-title":"Oncotarget"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1101\/gad.244368.114","article-title":"CDK9-Mediated Transcription Elongation Is Required for MYC Addiction in Hepatocellular Carcinoma","volume":"28","author":"Huang","year":"2014","journal-title":"Genes Dev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10637-018-0661-2","article-title":"CDKI-73: An Orally Bioavailable and Highly Efficacious CDK9 Inhibitor against Acute Myeloid Leukemia","volume":"37","author":"Rahaman","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Cicenas, J., and Simkus, J. (2024). CDK Inhibitors and FDA: Approved and Orphan. Cancers, 16.","DOI":"10.3390\/cancers16081555"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"108577","DOI":"10.1016\/j.bioorg.2025.108577","article-title":"Design, Synthesis, and Biological Evaluation of N-(2-Amino-Phenyl)-5-(4-Aryl- Pyrimidin-2-Yl) Amino)-1H-Indole-2-Carboxamide Derivatives as Novel Inhibitors of CDK9 and Class I HDACs for Cancer Treatment","volume":"162","author":"Chen","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1038\/s41467-022-30581-4","article-title":"Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 2 with a Highly Selective Inhibitor for the Treatment of Prostate Cancer","volume":"13","author":"Yuan","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/gcc.20136","article-title":"Novel Regions of Chromosomal Amplification at 6p21, 5p13, and 12q14 in Gastric Cancer Identified by Array Comparative Genomic Hybridization","volume":"42","author":"Gorringe","year":"2005","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/ijc.23380","article-title":"HMGA2 Is the Partner of MDM2 in Well-Differentiated and Dedifferentiated Liposarcomas Whereas CDK4 Belongs to a Distinct Inconsistent Amplicon","volume":"122","author":"Italiano","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"24881","DOI":"10.1073\/pnas.1912033116","article-title":"Inhibition of Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 2 Perturbs 26S Proteasome-Addicted Neoplastic Progression","volume":"116","author":"Banerjee","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/15384101.2016.1151728","article-title":"The 26S Proteasome: A Cell Cycle Regulator Regulated by Cell Cycle","volume":"15","author":"Guo","year":"2016","journal-title":"Cell Cycle"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1021\/acs.jmedchem.2c01718","article-title":"Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Inhibitors of CDK8 for the Treatment of Cancer","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1007\/s10620-013-2867-7","article-title":"The Up-Regulation of Histone Deacetylase 8 Promotes Proliferation and Inhibits Apoptosis in Hepatocellular Carcinoma","volume":"58","author":"Wu","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.lfs.2018.09.040","article-title":"Synergistic Activity of Imatinib and AR-42 against Chronic Myeloid Leukemia Cells Mainly through HDAC1 Inhibition","volume":"211","author":"Wei","year":"2018","journal-title":"Life Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"116839","DOI":"10.1016\/j.biopha.2024.116839","article-title":"Discovery of a Dual-Target DYRK2 and HDAC8 Inhibitor for the Treatment of Hepatocellular Carcinoma","volume":"177","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/20974","article-title":"Structure and Ligand of a Histone Acetyltransferase Bromodomain","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Boyson, S.P., Gao, C., Quinn, K., Boyd, J., Paculova, H., Frietze, S., and Glass, K.C. (2021). Functional Roles of Bromodomain Proteins in Cancer. Cancers, 13.","DOI":"10.3390\/cancers13143606"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of Bromodomain-Containing Proteins and Their Roles in Homeostasis and Cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"102323","DOI":"10.1016\/j.cbpa.2023.102323","article-title":"Bromodomain Inhibitors and Therapeutic Applications","volume":"75","author":"Gajjela","year":"2023","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13014-019-1345-6","article-title":"Pancreatic Ductal Adenocarcinoma: Biological Hallmarks, Current Status, and Future Perspectives of Combined Modality Treatment Approaches","volume":"14","author":"Orth","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1073\/pnas.1406722111","article-title":"BET and HDAC Inhibitors Induce Similar Genes and Biological Effects and Synergize to Kill in Myc-Induced Murine Lymphoma","volume":"111","author":"Bhadury","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_137","first-page":"1","article-title":"Combined Inhibition of BET Proteins and Class I HDACs Synergistically Induces Apoptosis in Urothelial Carcinoma Cell Lines","volume":"10","author":"Schulz","year":"2018","journal-title":"Clin. Epigenet."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"21507","DOI":"10.18632\/oncotarget.4242","article-title":"Combining BET and HDAC Inhibitors Synergistically Induces Apoptosis of Melanoma and Suppresses AKT and YAP Signaling","volume":"6","author":"Heinemann","year":"2015","journal-title":"Oncotarget"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1021\/acschembio.3c00427","article-title":"Development of Potent Dual BET\/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization","volume":"19","author":"Bauer","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Manduca, N., Maccafeo, E., De Maria, R., Sistigu, A., and Musella, M. (2023). 3D Cancer Models: One Step Closer to in Vitro Human Studies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1175503"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Chilamakuri, R., and Agarwal, S. (2022). Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth. Cancers, 14.","DOI":"10.3390\/cancers14041067"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Heged\u00fcs, L., Qaisieh, S., St\u00fclpnagel, C., Ganjeh Khor Dezfouli, Y., Tambo, W., Doerr, F., Baldes, N., Theegarten, D., Schuler, M., and B\u00f6l\u00fckbas, S. (2025). Dual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression. Cells, 14.","DOI":"10.3390\/cells14201599"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1002\/ctm2.678","article-title":"Patient-Derived Organoids for Personalized Gallbladder Cancer Modelling and Drug Screening","volume":"12","author":"Yuan","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"RCR5189","DOI":"10.59761\/RCR5189","article-title":"Monocarbonyl Synthetic Curcumin Analogues with Antitumour Potential. Chemical and Biological Aspects","volume":"94","author":"Neganova","year":"2025","journal-title":"Russ. Chem. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6604\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:13:59Z","timestamp":1785298439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":144,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27156604"],"URL":"https:\/\/doi.org\/10.3390\/ijms27156604","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}